Sales momentum continued for DR/CR digital products. Large orders were secured for DR products in North America. The B2B business is on the rise and its sales channels are steadily expanding in the overseas market. A sales agreement for AeroDR was concluded with GE Healthcare in June for the global market. A switch was made to outsourced production for dry film, and active efforts were made to pursue sales in emerging countries.
I would like to take the opportunity to briefly discuss the acquisition of the ultrasonic diagnostic equipment business from Panasonic Healthcare Co., Ltd., which was announced last week.
First, let's look at the aim of the acquisition. Konica Minolta is promoting a "genre-top strategy" in the Business Technologies Business, the main business of the company. We formulated a target of being ahead of the competition based on the company's specialist domains. The concept underpinning the "genre-top strategy" is to secure top position in these domains. The "genre-top strategy" is being rolled out in the Healthcare Business as well, and AeroDR, which I mentioned before, has secured top domestic share in cassette-type digital radiography systems. Ultrasonic diagnostic equipment is also being promoted as part of the "genre-top strategy."
The Group will provide revolutionary image quality by leveraging unique technology and develop business mainly targeting orthopedics and clinical oncology. We will be able to make the most of synergy with the traditional radiography channel, providing us with a sufficient chance of leading the competition.
Although we are unable to disclose the exact acquisition amount due to confidentiality obligations with the other party, we can say that it is not to the extent that has been reported in the newspaper. Konica Minolta's basic policy for M&As is to acquire only that portion required for the strategy at an appropriate price.
I would like to take the opportunity to briefly discuss the acquisition of the ultrasonic diagnostic equipment business from Panasonic Healthcare Co., Ltd., which was announced last week.
First, let's look at the aim of the acquisition. Konica Minolta is promoting a "genre-top strategy" in the Business Technologies Business, the main business of the company. We formulated a target of being ahead of the competition based on the company's specialist domains. The concept underpinning the "genre-top strategy" is to secure top position in these domains. The "genre-top strategy" is being rolled out in the Healthcare Business as well, and AeroDR, which I mentioned before, has secured top domestic share in cassette-type digital radiography systems. Ultrasonic diagnostic equipment is also being promoted as part of the "genre-top strategy."
The Group will provide revolutionary image quality by leveraging unique technology and develop business mainly targeting orthopedics and clinical oncology. We will be able to make the most of synergy with the traditional radiography channel, providing us with a sufficient chance of leading the competition.
Although we are unable to disclose the exact acquisition amount due to confidentiality obligations with the other party, we can say that it is not to the extent that has been reported in the newspaper. Konica Minolta's basic policy for M&As is to acquire only that portion required for the strategy at an appropriate price.